Cargando…
ARDS infolge schwerer RSV-Infektion Therapeutische Optionen: Therapeutische Optionen
We report on a strikingly frequent referral of former preterm babies with respiratory syncytial virus (RSV) infection and subsequent ARDS in our hospital during the winter 1994/95 with regard to the clinical course under application of alternative treatment modalities. Treatment modalities like inha...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095882/ https://www.ncbi.nlm.nih.gov/pubmed/32226141 http://dx.doi.org/10.1007/s001120050095 |
_version_ | 1783510704443097088 |
---|---|
author | Varnholt, V. Lasch, P. Suske, G. Koelfen, W. Kachel, W. |
author_facet | Varnholt, V. Lasch, P. Suske, G. Koelfen, W. Kachel, W. |
author_sort | Varnholt, V. |
collection | PubMed |
description | We report on a strikingly frequent referral of former preterm babies with respiratory syncytial virus (RSV) infection and subsequent ARDS in our hospital during the winter 1994/95 with regard to the clinical course under application of alternative treatment modalities. Treatment modalities like inhalational ribavirin, use of bronchodilators and instillation of surfactant had been tried without success. All children (age: 1–43 months) were ventilated for 6.6 (1–17) days with FiO(2) = 1.0 and a mean airway pressure of 16.4 (10–24) cm H(2)O. Mean arterial blood gases were 49 (paO(2)) and 41 (pCO(2)) mm Hg, the OI was 33.4. By inhalational NO in combination with IPPV or HFOV 4 patients could be stabilized, in the other 6 ECMO became necessary. Two of them died in spite of several weeks on ECMO; 8 children survived and could be discharged home after a mean hospital stay of 3 months. Even in very severe cases of RSV infection treatment modalities like NO, HFOV and ECMO can be used successfully. The use of these treatment modalities must be considered before the lung damage is irreversible; in those cases a pre-existing BPD is no contraindication even for extracorporeal lung support. |
format | Online Article Text |
id | pubmed-7095882 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1996 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-70958822020-03-26 ARDS infolge schwerer RSV-Infektion Therapeutische Optionen: Therapeutische Optionen Varnholt, V. Lasch, P. Suske, G. Koelfen, W. Kachel, W. Monatsschr Kinderheilkd Pädiatrische Praxis We report on a strikingly frequent referral of former preterm babies with respiratory syncytial virus (RSV) infection and subsequent ARDS in our hospital during the winter 1994/95 with regard to the clinical course under application of alternative treatment modalities. Treatment modalities like inhalational ribavirin, use of bronchodilators and instillation of surfactant had been tried without success. All children (age: 1–43 months) were ventilated for 6.6 (1–17) days with FiO(2) = 1.0 and a mean airway pressure of 16.4 (10–24) cm H(2)O. Mean arterial blood gases were 49 (paO(2)) and 41 (pCO(2)) mm Hg, the OI was 33.4. By inhalational NO in combination with IPPV or HFOV 4 patients could be stabilized, in the other 6 ECMO became necessary. Two of them died in spite of several weeks on ECMO; 8 children survived and could be discharged home after a mean hospital stay of 3 months. Even in very severe cases of RSV infection treatment modalities like NO, HFOV and ECMO can be used successfully. The use of these treatment modalities must be considered before the lung damage is irreversible; in those cases a pre-existing BPD is no contraindication even for extracorporeal lung support. Springer-Verlag 1996 /pmc/articles/PMC7095882/ /pubmed/32226141 http://dx.doi.org/10.1007/s001120050095 Text en © Springer-Verlag Berlin Heidelberg 1996 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Pädiatrische Praxis Varnholt, V. Lasch, P. Suske, G. Koelfen, W. Kachel, W. ARDS infolge schwerer RSV-Infektion Therapeutische Optionen: Therapeutische Optionen |
title | ARDS infolge schwerer RSV-Infektion
Therapeutische Optionen: Therapeutische Optionen |
title_full | ARDS infolge schwerer RSV-Infektion
Therapeutische Optionen: Therapeutische Optionen |
title_fullStr | ARDS infolge schwerer RSV-Infektion
Therapeutische Optionen: Therapeutische Optionen |
title_full_unstemmed | ARDS infolge schwerer RSV-Infektion
Therapeutische Optionen: Therapeutische Optionen |
title_short | ARDS infolge schwerer RSV-Infektion
Therapeutische Optionen: Therapeutische Optionen |
title_sort | ards infolge schwerer rsv-infektion
therapeutische optionen: therapeutische optionen |
topic | Pädiatrische Praxis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095882/ https://www.ncbi.nlm.nih.gov/pubmed/32226141 http://dx.doi.org/10.1007/s001120050095 |
work_keys_str_mv | AT varnholtv ardsinfolgeschwererrsvinfektiontherapeutischeoptionentherapeutischeoptionen AT laschp ardsinfolgeschwererrsvinfektiontherapeutischeoptionentherapeutischeoptionen AT suskeg ardsinfolgeschwererrsvinfektiontherapeutischeoptionentherapeutischeoptionen AT koelfenw ardsinfolgeschwererrsvinfektiontherapeutischeoptionentherapeutischeoptionen AT kachelw ardsinfolgeschwererrsvinfektiontherapeutischeoptionentherapeutischeoptionen |